218 related articles for article (PubMed ID: 33246984)
21. Combined inhibition/silencing of diacylglycerol kinase α and ζ simultaneously and synergistically enhances interleukin-2 production in T cells and induces cell death of melanoma cells.
Takao S; Akiyama R; Sakane F
J Cell Biochem; 2021 May; 122(5):494-506. PubMed ID: 33399248
[TBL] [Abstract][Full Text] [Related]
22. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.
Binder DC; Engels B; Arina A; Yu P; Slauch JM; Fu YX; Karrison T; Burnette B; Idel C; Zhao M; Hoffman RM; Munn DH; Rowley DA; Schreiber H
Cancer Immunol Res; 2013 Aug; 1(2):123-33. PubMed ID: 24455752
[TBL] [Abstract][Full Text] [Related]
23. The diacylglycerol kinase ζ inhibitor ASP1570 augments natural killer cell function.
Okumura M; Yokoyama Y; Yoshida T; Okada Y; Takizawa M; Ikeda O; Kambayashi T
Int Immunopharmacol; 2023 Dec; 125(Pt A):111145. PubMed ID: 37935092
[TBL] [Abstract][Full Text] [Related]
24. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
25. Diacylglycerol kinase ζ limits B cell antigen receptor-dependent activation of ERK signaling to inhibit early antibody responses.
Wheeler ML; Dong MB; Brink R; Zhong XP; DeFranco AL
Sci Signal; 2013 Oct; 6(297):ra91. PubMed ID: 24129701
[TBL] [Abstract][Full Text] [Related]
26. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
27. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
29. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
30. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals.
Arranz-Nicolás J; Ogando J; Soutar D; Arcos-Pérez R; Meraviglia-Crivelli D; Mañes S; Mérida I; Ávila-Flores A
Cancer Immunol Immunother; 2018 Jun; 67(6):965-980. PubMed ID: 29572701
[TBL] [Abstract][Full Text] [Related]
31. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
32. Conditional Deletion of
Raghavan S; Tovbis-Shifrin N; Kochel C; Sawant A; Mello M; Sathe M; Blumenschein W; Muise ES; Chackerian A; Pinheiro EM; Rosahl TW; Luche H; de Waal Malefyt R
Front Immunol; 2021; 12():752348. PubMed ID: 34912335
[TBL] [Abstract][Full Text] [Related]
33. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
[TBL] [Abstract][Full Text] [Related]
34. PD-1
Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
[No Abstract] [Full Text] [Related]
35. CD8
Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
[TBL] [Abstract][Full Text] [Related]
36. TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.
Menger L; Sledzinska A; Bergerhoff K; Vargas FA; Smith J; Poirot L; Pule M; Hererro J; Peggs KS; Quezada SA
Cancer Res; 2016 Apr; 76(8):2087-93. PubMed ID: 27197251
[TBL] [Abstract][Full Text] [Related]
37. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
38. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.
Ren Z; Zhang A; Sun Z; Liang Y; Ye J; Qiao J; Li B; Fu YX
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104810
[TBL] [Abstract][Full Text] [Related]
39. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
[TBL] [Abstract][Full Text] [Related]
40. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]